The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Comparing the JCOG1109 and ESOPEC trials in esophageal cancer
Ken Kato, MD, PhD, National Cancer Center Hospital East, Tokyo, Japan, discusses critical factors in selecting treatment for esophageal squamous cell carcinoma (ESCC). Results from the ESOPEC trial (NCT02509286), comparing neoadjuvant chemoradiotherapy and perioperative triplet chemotherapy, align with the JCOG1109 trial (NCT02188699). Findings indicate that neoadjuvant chemoradiotherapy does not improve survival compared to the triplet docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen, which enhances resection and survival rates. The role of immune checkpoint inhibitors in combination with chemotherapy is also examined. This interview took place during the 2024 ASCO Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role – Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers’ Bureau – Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding – AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
